Early endometrial carcinoma: Experience and outcomes
Priyanka Goel1, Vikram Singh1, Rakesh Sharma1, Debashish Chaudhary1, Abhishek Chatterjee2, Tapas Dora1, Sankalp Sancheti1, Alok Goel1, Sachin Khandelwal1, Akash Pramod Sali1, Harpreet Kaur3, Arvind Guru2, Rakesh Kapoor1
1 Department of Departments of Surgical Oncology, Radiation Oncology, Medical Oncology and Pathology, Homi Bhabha Cancer Hospital, Sangrur, Punjab, India
2 Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
3 Department of Nursing, Homi Bhabha Cancer Hospital, Sangrur, Punjab, India
Homi Bhabha Cancer Hospital, Civil Hospital Campus, Sangrur - 148 001, Punjab
Source of Support: None, Conflict of Interest: None
Aim: Endometrial carcinoma (EC) data from India are very sparse. We did a retrospective analysis of our patients registered at this peripheral cancer center based in rural Punjab and studied their outcome.
Materials and Methods: Ninety-eight Stage I and II EC patients with endometroid histology registered at our institute from January 2015 to April 2020 were studied for demography, histopathology, treatment received, and outcomes. FIGO 2009 staging and new European Society for Medical Oncology (ESMO) risk group classification was used.
Results: Our patients had a median age of 60 years (range 32–93 years). There were 39 (39.8%), 41 (42.0%), 4 (4.1%), 12 (12.2%) patients in the low risk, intermediate risk (IR), high intermediate risk, and high risk groups, respectively, as per new ESMO risk classification. Two (2.0%) patients had incomplete information to assign them to a particular risk group. Fifty (46.7%) patients underwent complete surgical staging and 54 (50.5%) patients received adjuvant RT. With a median follow-up of 27.0 months, there were 1 locoregional and 2 distant recurrences. There were 8 deaths in total. Three-year overall survival for the entire group is 90.6%.
Conclusions: The risk group determines adjuvant treatment in endometrial cancer. Patients operated at dedicated cancer center tend to have better surgical staging and thus better outcome because of better risk stratification and grouping for adjuvant therapy. IR histology was more common in our group of patients, which is variable as compared to available literature.